AccurKardia’s Post

Cardio Explorer offers a non-invasive way to detect life-threatening narrowing in the coronary arteries with the help of AI. With an impressive accuracy (AUC of 0.87) rivaling the best imaging techniques, this AI device empowers both physicians and patients with precise insights and reliable results. It’s designed to meet ESC 2024 guidelines with higher precision, aiding in efficient risk stratification for suspected coronary heart disease.  Stay proactive about heart health with Cardio Explorer: https://lnkd.in/gYSX66rq  #AlfaDiag #AIDiagnostics #Healthcare #HealthcareSolutions #Diagnostics #InnovativeDiagnostics #DiseaseDetection #ArtificialIntelligence #AI #CardioExplorer #Cardiology #ChronicDisease

The clinical application value of artificial intelligence ECG monitoring for arrhythmia detection To investigate the clinical application value of artificial intelligence ECG ( AI-ECG) monitoring for arrhythmia detection, the First Hospital Affiliated to Hebei North College enrolled a total of 1,240 patients and made a comparison between AI-ECG group (using 24h holter patch ER1-LB and AI diagnosis) and Holter group (using 24h conventional holter and manual diagnosis).   The result shows that ECG processing time in the AI-ECG group was significantly shorter than that in the Holter group (the AI-ECG is 5.26 ±0.82 minutes while the Holter group is 7.68 +0.55 minutes). The positive diagnosis rate of arrhythmia AI-ECG group was 68. 87% ( 854/1,240) , which was significantly higher than that [38.87% (482/1,240) ] in Holter group.  In this study we come to a conclusion that the AI-ECG monitoring can perform early warning, early finding and early treatment for malignant arrhythmia events, so as to improve the success rate of emergency treatment and reduce the mortality rate, which has good clinical application prospects. Click here to get more info. >>https://lnkd.in/dut3vQTH Contact us 📧>> ryan.geng@lepu-medical.com #Artificialintelligence #ECG #holter #Cardiology #Arrhythmia 

Detecting disease early has numerous benefits for #valuebasedcare and #feeforservice arrangements. Hospitals and health systems-what does finding stage B heart disease (as an example) mean for you? Aside from the clinical benefits to the patient how much cost is avoided when catching disease in its earliest stages? Eko Health #SENSORA is the only AI tool of its kind-powered by our #CORE stethoscopes. The technology allows for medical assistants in a PCP or urgent care environment to detect heart disease before it is too late. Become a heart hero and join the movement! #ekoproud #heartdisease #vhd #lowef #HFrEF #heartfailure #earlydetectionmatters

The clinical application value of artificial intelligence ECG monitoring for arrhythmia detection To investigate the clinical application value of artificial intelligence ECG ( AI-ECG) monitoring for arrhythmia detection, the First Hospital Affiliated to Hebei North College enrolled a total of 1,240 patients and made a comparison between AI-ECG group (using 24h holter patch ER1-LB and AI diagnosis) and Holter group (using 24h conventional holter and manual diagnosis).   The result shows that ECG processing time in the AI-ECG group was significantly shorter than that in the Holter group (the AI-ECG is 5.26 ±0.82 minutes while the Holter group is 7.68 +0.55 minutes). The positive diagnosis rate of arrhythmia AI-ECG group was 68. 87% ( 854/1,240) , which was significantly higher than that [38.87% (482/1,240) ] in Holter group.  In this study we come to a conclusion that the AI-ECG monitoring can perform early warning, early finding and early treatment for malignant arrhythmia events, so as to improve the success rate of emergency treatment and reduce the mortality rate, which has good clinical application prospects. Click here to get more info. >>https://lnkd.in/eEqtf7cd Contact us 📧>> Evelyn.Liu@lepu-medical.com #Artificialintelligence #ECG #holter #Cardiology #Arrhythmia 

The clinical application value of artificial intelligence ECG monitoring for arrhythmia detection To investigate the clinical application value of artificial intelligence ECG ( AI-ECG) monitoring for arrhythmia detection, the First Hospital Affiliated to Hebei North College enrolled a total of 1,240 patients and made a comparison between AI-ECG group (using 24h holter patch ER1-LB and AI diagnosis) and Holter group (using 24h conventional holter and manual diagnosis).   The result shows that ECG processing time in the AI-ECG group was significantly shorter than that in the Holter group (the AI-ECG is 5.26 ±0.82 minutes while the Holter group is 7.68 +0.55 minutes). The positive diagnosis rate of arrhythmia AI-ECG group was 68. 87% ( 854/1,240) , which was significantly higher than that [38.87% (482/1,240) ] in Holter group.  In this study we come to a conclusion that the AI-ECG monitoring can perform early warning, early finding and early treatment for malignant arrhythmia events, so as to improve the success rate of emergency treatment and reduce the mortality rate, which has good clinical application prospects. Click here to get more info. >>https://lnkd.in/dR2JXE_J Contact us 📧>> chailyn.qin@lepu-medical.com #Artificialintelligence #ECG #holter #Cardiology #Arrhythmia 

AI-tailored pulmonary vein isolation ("PVI-plus") shows promising success over traditional PVI in trial results recently presented at the Heart Rhythm Society meeting in Boston. The trial leveraged the VX1 technology from Volta Medical in treatment of persistent atrial fibrillation (AF). Trial results from the TAILORED-AF trial met primary efficacy endpoint of superior freedom from AF at 12 months in the PVI-plus group v. traditional PVI. Freedom from AF at 12 months with the AI-guided procedure was observed in 66% of patients v. only 15% in the traditional PVI group. The trial did not meet its secondary endpoint of freedom from any arrhythmia, with isolated flutter present in both groups. Interestingly, the extra mapping and data gathering required for the AI procedure resulted in significantly longer procedure times (almost 2x longer) and greater fluoroscopy use. The trial design included both traditional in-office ECG follow-up / Holter monitoring and digital health data acquisition with weekly 6-lead ECG monitoring using the Kardia smartphone app. That's a lot of data! Overall a promising application of AI for a challenging clinical condition in which traditional treatment still leaves much to be desired. Obviously AF can be a common side effect of structural heart interventions, would be particularly interesting from that perspective to see how Volta's technical might be used to better understand the development of arrhythmias after therapies that are as 'simple' as mitral TEER. Volta VX1 510(k) summary: https://lnkd.in/gcUqSPRv Clinical Trials info: https://lnkd.in/gwfDF42G TCTMD write-up: https://lnkd.in/gM6uBVHc (image in post from Volta's website)

The clinical application value of artificial intelligence ECG monitoring for arrhythmia detection To investigate the clinical application value of artificial intelligence ECG ( AI-ECG) monitoring for arrhythmia detection, the First Hospital Affiliated to Hebei North College enrolled a total of 1,240 patients and made a comparison between AI-ECG group (using 24h holter patch ER1-LB and AI diagnosis) and Holter group (using 24h conventional holter and manual diagnosis).   The result shows that ECG processing time in the AI-ECG group was significantly shorter than that in the Holter group (the AI-ECG is 5.26 ±0.82 minutes while the Holter group is 7.68 +0.55 minutes). The positive diagnosis rate of arrhythmia AI-ECG group was 68. 87% ( 854/1,240) , which was significantly higher than that [38.87% (482/1,240) ] in Holter group.  In this study we come to a conclusion that the AI-ECG monitoring can perform early warning, early finding and early treatment for malignant arrhythmia events, so as to improve the success rate of emergency treatment and reduce the mortality rate, which has good clinical application prospects. Click here to get more info. >>https://lnkd.in/gR9Ez2UF Contact us 📧>> flora.lv@lepu-medical.com #Artificialintelligence #ECG #holter #Cardiology #Arrhythmia 

💥 3D-LGE-CMR can non-invasively identify SCAIs in rToF patients. 📊 3D-LGE-CMR had (derivation/validation cohorts) a high sensitivity (100%/95%) and specificity (90%/91%) in identifying SCAIs compared to invasive EAM. 👎 Current risk sores were worse (best AUC was 0.65) for predicting SCAIs. 😏 Ventriculotomy, palliation, reduced LVEF were significantly associated with SCAIs, while PR was NOT. 🛠️ Promising tool for better non-invasive risk stratification in rToF.

Take Control of Neurotrophic Keratitis—Act Early! Physicians, be proactive and routinely test for sensitivity with dry eye patients. Contact your local BioTissue Representative today to discover how our solutions may improve NK patient outcomes. Learn more about Prokera® for NK: https://lnkd.in/gyfXf94t #BioTissue #Ocular #Optometry #NeurotrophicKeratitis

🌍 It's exciting to see external validations of our #PMcardio OMI AI Model from around the world, driven by pioneers like Dr. Sascha Macherey-Meyer and Dr. Christoph Adler from Uniklinik Köln. This study, presented at the biggest German cardiology congress – the 90th DGK Annual Meeting, showcased remarkable diagnostic results for occlusion myocardial infarction.   🔍 Key Highlights from the Validation: 🔹 1,770 chest pain patients evaluated 🔹 diagnostic accuracy of 95.3% 🏥 This study evaluated a retrospective cohort of acute chest pain patients who did not meet the traditional STEMI criteria and presented to German Chest Pain Units (CPU) over the course of 1 year. The outcomes emphasize the model’s precision and robust potential in emergencies, particularly its ability to accurately exclude acute occlusive myocardial infarctions with a specificity of 98.9% and a 100% negative predictive value. 🇩🇪 For more detailed insights, visit: https://lnkd.in/gPY-MEMq 💙 We're grateful to all our cooperating centers and look forward to welcoming more partners as we continue to push the boundaries of cardiovascular diagnostics using AI, with the ultimate goal of improving patient outcomes. #PowerfulMedical #UniklinikKöln #AIinHealthcare #ACS Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V.